Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2Ventricular Dysfunction 1Radiation Pneumonitis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hypertension 1Essential Hypertension 1Cardiotoxicity 1Barrett Esophagus 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Enalapril × Clear all
NCT01151410 2016-03-07

An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

Novartis

Phase 3 Completed
208 enrolled 10 charts

Essential Hypertension, Hypertension, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡